相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis
Martin J. Boeree et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
Rodney Dawson et al.
LANCET (2015)
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
Corinne S. Merle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Stephen H. Gillespie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Amina Jindani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients
Erlina Burhan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Cost-effectiveness of novel first-line treatment regimens for tuberculosis
J. P. Owens et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium
Susan E. Dorman et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Shortening Treatment in Adults with Noncavitary Tuberculosis and 2-Month Culture Conversion
John L. Johnson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Tuberculosis pharmacotherapy: strategies to optimize patient care
Carole D. Mitnick et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs
G. R. Davies et al.
TUBERCULOSIS (2008)
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears
A. H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Optimal sampling strategies for early pharmacodynamic measures in tuberculosis
G. R. Davies et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
William J. Burman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
H McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis
R Ruslami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis
FA Sirgel et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Antimicrobial pharmacodynamics: Critical interactions of 'bug and drug'
GL Drusano
NATURE REVIEWS MICROBIOLOGY (2004)
Antimicrobial therapy of tuberculosis: Justification for currently recommended treatment regimens
DA Mitchison
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The role of rifampicin in the management of cutaneous leishmaniasis
DK Kochar et al.
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS (2000)
分享论文
